ABSTRACT
Chronic inflammatory response syndrome (CIRS) is a multi-symptom, multisystem illness that profoundly affects the central nervous system (CNS). Manifestations of CIRS in the CNS include unique fingerprints on volumetric magnetic resonance imaging (MRI) (NeuroQuant®). Recent advances in the transcriptomics test GENIE (Genomic expression: Inflammation Explained) offer greater insight into how molecular hypometabolism relates to inflammation, metabolism, coagulation and proliferative physiology. Azole antifungals contribute to grey matter atrophy via tubulin disruption. CIRS profoundly affects the hypothalamus, and disturbances occur in melanocyte stimulating hormone (MSH), vasoactive intestinal peptide (VIP) and antidiuretic hormone (ADH). CIRS can contribute to mood disorders and particularly suicidality. Abnormalities in CIRS biomarkers can occur in patients with headaches, postural orthostatic tachycardia syndrome (POTS), chronic pain, movement disorders, pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorder associated with streptococcal infections (PANDAS), and psychiatric conditions. CIRS has profound implications relating to dementia and cognitive decline. The work by Dr. Sidney Strickland in the vascular theory of dementia provides new insights into the processes of cognitive decline and raises the question of what role CIRS may play. Universal and targeted screening of CIRS may reduce dysregulation of the innate immune system and benefit patients with numerous and varied neurologic conditions.
